Long enough.

Might mean forever if talking about androgen deprivation therapy (ADT) for very high risk prostate cancer. This meta-analysis examined the effects of length of ADT on survival among men with high Gleason (≥8) prostate cancer. It included almost 1K patients with high Gleason scores enrolled across 6 clinical trials assessing various durations (including no) ADT in combo with definitive radiation. For patients with Gleason 8 disease, long-term ADT of at least 28 months conferred the lowest hazard ratio for death (0.43). For patients with Gleason 9-10 disease, lifelong ADT was the winning regimen with a hazard ratio of  0.48. TBL: As suggested, more ADT probably means more relative prostate cancer control...which inevitably confers the most benefit in those with the highest risk disease. | Kishan, JAMA Oncol 2018


  1. Hi, Shared knowledge by you seems very useful for cancer patients. Medical field gets more success to fail big diseases. Thanks for sharing this updated news with us. I would like to prefer such best news sites which provide updated news.


Post a Comment

Popular Posts